PATENT CLAIM ANALYSIS

Application Number: 15776933
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["546", "192000"]

Abstract:
The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

Claim (Index 2):
A compound of  claim 1  where:\n Ar 1  is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, furanyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazinyl, oxadiazolyl, thiadiazolyl, or benzodioxyl, and is substituted with 1-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, and SO 2 R 6 ; \n Ar 2  is phenyl or pyridinyl substituted with 0-3 substituents selected from from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy; \n Ar 3  is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyridinonyl, pyrrolyl, furanyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazinyl, oxadiazolyl, thiadiazolyl, or benzodioxyl and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (NR 1 R 2 )alkyl, hydroxy, alkoxy, haloalkoxy, cycloalkoxy, NR 1 R 2 , CO 2 R 3 , CONR 4 R 5 , and SO 2 R 6 ; \n R 1  is hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, or haloalkylsulfonyl; \n R 2  is hydrogen or alkyl; \n or NR 1 R 2  taken together is selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, and morpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, haloalkyl, alkoxy, and haloalkoxy; \n R 3  is hydrogen or alkyl; \n R 4  is hydrogen, alkyl, or (R 7 R 8 N)alkyl; \n R 5  is hydrogen or alkyl; \n or NR 4 R 5  taken together is selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, and morpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, haloalkyl, alkoxy, and haloalkoxy; \n R 6  is alkyl or R 7 R 8 N; \n R 7  is hydrogen or alkyl; \n R 8  is hydrogen or alkyl; \n or NR 7 R 8  taken together is selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, and morpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, haloalkyl, alkoxy, and haloalkoxy; and \n X is hydrogen, halo, hydroxy, or alkoxy; \n or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 93.0
- Lexical Diversity: 1.51163
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12266627', '16092075', '13439096', '15776936', '14443944']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7793304777062894
- 35 USC 102 Novelty (BERT): 0.5085966485170152
- Combined Prediction Score: 0.752257094787362
- Mean Citation Score: 290.95728
- Max Citation Score: 300.5118700000001
- Similarity Product: 274.0717155328859

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test